Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
Epirubicin for the Treatment of Sepsis & Septic Shock
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05033808
- Locations
- 🇩🇪
University Medicine Greifswald, Greifswald, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Germany
🇩🇪Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
- Conditions
- Bladder CancerNon-muscle Invasive
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Roland Seiler-Blarer
- Target Recruit Count
- 34
- Registration Number
- NCT05024734
- Locations
- 🇨🇭
Spitalzentrum Biel/Bienne, Biel, Switzerland
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- University of Thessaly
- Target Recruit Count
- 180
- Registration Number
- NCT04947059
- Locations
- 🇬🇷
Urology Department, University of Thessaly, University Hospital of Larissa, Larissa, Larissa/Thessaly, Greece
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Conditions
- Intravascular Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04899570
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04877821
- Locations
- 🇨🇳
NeoSACT, Guangzhou, Guangdong, China
Pyrotinib in Combination with Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: a Phase II Trial
- Conditions
- Breast CancerHormone-receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 140
- Registration Number
- NCT04872985
- Locations
- 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China
MicroRNA Profiles in Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- University College Hospital, Ibadan
- Target Recruit Count
- 42
- Registration Number
- NCT04771871
- Locations
- 🇳🇬
Lagos State University Teaching Hospital, Lagos, Nigeria
🇳🇬Lagos University Teaching Hospital, Lagos, Nigeria
🇳🇬Obafemi Awolowo University Teaching Hospital, Ile-Ife, Oshun, Nigeria
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy
- Conditions
- Triple-negative Breast Cancer
- Interventions
- Procedure: Biopsy Arm BProcedure: Biopsy Arm AProcedure: Surgery
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 416
- Registration Number
- NCT04770272
- Locations
- 🇩🇪
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;, Bottrop, Germany
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 226
- Registration Number
- NCT04738188
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, China
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Target Recruit Count
- 800
- Registration Number
- NCT04736394
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.